Healtcare Linear Accelerators for Radiation Market | Page 2

people living with cancer can access safe and effective treatment. Moreover, Cancer Research UK
organized Early Diagnosis Research Conference in February 2017, to share and discuss latest
developments in early diagnosis research.
Growth of the linear accelerators for radiation market size is driven by increasing prevalence and
incidence of various types of cancer, along with growing patient awareness programs by
government and private organizations, and rising adoption of radiotherapy in cancer treatment. For
instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer
cases in 2012. Moreover, India, China, and other East and Central Asian countries accounted for
nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the same
source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4 million cancer
deaths, in less developed regions.
According to data findings by the World Health Organization (WHO), in February 2018, cancer is
the second-leading cause of death globally, accounting for 8.8 million deaths in 2015. Also, the
number of new cases of cancer is expected to rise by 70% in the near future, globally, according to
the same source. According to the International Agency for Research on Cancer (IARC), in 2012, an
estimated 14.1 million new cancer cases were reported. Among these, the most common form of
cancer was lung cancer (13%), breast cancer (11.9%), and colorectal cancer (9.7%), globally.
According to the World Cancer Research Fund (WCRF) International, 2015 data findings, 58% of
the lung cancer cases were reported in the emerging economies, in 2014. Hungary had the highest
rate of lung cancer, followed by Serbia, and North Korea. Moreover, highest incidence of lung
cancer was registered in North America and Europe, for the same year. Moreover, according to the
Cancer Research UK, 2015 statistics, 55,122 new cases of breast cancer were registered in 2015,
U.K. In the U.K., breast cancer was the most common cancer, accounting for 15% of all new cancer
cases in 2015. Furthermore, in 2014, 7% cases of breast cancer were registered among the total
cancer deaths in the U.K., according to the same source.
Linear Accelerators for Radiation Market Restraints
Major concerns of affordability and accessibility for the treatment, lack of trained personnel to
operate linear accelerators, are some of the limiting factors, which may hinder the future market
growth for linear accelerators for radiation.
Linear Accelerators for Radiation Market – Regional Analysis
Geographically, global linear accelerators for radiation market is segmented into North America,
Latin America, Europe, Middle East, Asia Pacific, and Africa. Growing adoption of linear
accelerators by prominent cancer treatment centers, worldwide; and upgrading the conventional
treatment, will augment growth of the linear accelerators for radiation market, in the near future. In
May 2016, Leeds Cancer Centre, a leading providers of cancer care in the U.K. updated its existing
treatment equipment with eight Elekta Versa HD linear accelerators. The Versa HD linear
accelerators combined with Volumetric Arc Therapy (VMAT) allows to deliver complex head and
neck cancer therapy up to 42% faster. Furthermore, in November 2017, Romanian government
signed for five Elekta linear accelerators, to supply the country with sophisticated radiation therapy
devices. In addition, Princess Margaret Cancer Centre from Canada and Odense University Hospital
from Denmark in December 2016, also ordered high-field MR-supported linear accelerator (MR-
linac). Both Versa HD linear accelerator and high-field MR-supported linear accelerator (MR-linac)
are manufactured by Elekta AB.
Linear Accelerators for Radiation Market – Competitor